Latest Comments

Minoryx’s MIN-102 secures orphan drug designation

Minoryx’s MIN-102 secures orphan drug designation

Competition is heating up in long-acting growth hormones for children

Competition is heating up in long-acting growth hormones for children

Promising preliminary data from Phase II study encourages Axovant to expand trial

Promising preliminary data from Phase II study encourages Axovant to expand trial

Still hope for Lirilumab-Opdivo combination despite disappointing monotherapy data

Still hope for Lirilumab-Opdivo combination despite disappointing monotherapy data

When faster is not better: the 'surrogate' example

When faster is not better: the 'surrogate' example

Persistence may be Novavax’s greatest asset in its quest to develop an RSV vaccine

Persistence may be Novavax’s greatest asset in its quest to develop an RSV vaccine

The importance of real world evidence in the 21st Century Cures Act

The importance of real world evidence in the 21st Century Cures Act

Positive Phase IIb results position Synthetic Biologics’ Ribaxamase as serious contender for C. difficile Prophylaxis

Positive Phase IIb results position Synthetic Biologics’ Ribaxamase as serious contender for C. difficile Prophylaxis

ImmunoGen is poised to solve a major unmet medical need in ovarian cancer

ImmunoGen is poised to solve a major unmet medical need in ovarian cancer

Eli Lilly lays off 485 employees following failure of solanezumab

Eli Lilly lays off 485 employees following failure of solanezumab

PD-1s show early promise in melanoma brain metastases

PD-1s show early promise in melanoma brain metastases

How biomarker-driven cancer immunotherapy can benefit both patients and developers

How biomarker-driven cancer immunotherapy can benefit both patients and developers

Phase III failure puts the future of Alcobra in doubt

Phase III failure puts the future of Alcobra in doubt

Eli Lilly aims to dominate the migraine market

Eli Lilly aims to dominate the migraine market

Hold on clinical trials of Vadastuximab Talirine may be temporary setback

Hold on clinical trials of Vadastuximab Talirine may be temporary setback

Intarcia Therapeutics' game-changing type 2 diabetes treatment is on the horizon

Intarcia Therapeutics' game-changing type 2 diabetes treatment is on the horizon

Merck’s Verubecestat marks a new era for Alzheimer’s treatment

Merck’s Verubecestat marks a new era for Alzheimer’s treatment

SIMPLIFY Results Complicate Gilead's Entry into the Myelofibrosis Market

SIMPLIFY Results Complicate Gilead's Entry into the Myelofibrosis Market

Inclisiran offers hope for dyslipidemia patients

Inclisiran offers hope for dyslipidemia patients

Alkermes' ALKS-5461 demonstrates positive Phase III efficacy at third attempt

Alkermes' ALKS-5461 demonstrates positive Phase III efficacy at third attempt